Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 9/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133466 | 0.85 | ADORA2A (0.41) | CYP1A2CLK1KDM4EALDH1A1POLB | |
| SCHEMBL6133302 | 0.83 | CYP1A2 (0.54) | CYP1A2ADORA2AADORA1 | |
| SCHEMBL6134067 | 0.82 | ADORA2A (0.49) | ALDH1A1DCUN1D1HSD17B10ADORA2AADORA1 | |
| SCHEMBL6133777 | 0.81 | ADORA1 (0.41) | CYP1A2CLK1AKR1B1ADORA2AADORA1 | |
| SCHEMBL6134475 | 0.80 | ADORA1 (0.41) | CYP1A2CLK1CDK5CDK5R1ALDH1A1 | |
| SCHEMBL11633235 | 0.79 | CYP1A2 (0.56) | CYP1A2AKR1B1KDM4EPOLBDCUN1D1 | |
| SCHEMBL6134600 | 0.79 | FGFR1 (0.42) | CYP1A2CLK1CDK5CDK5R1POLB | |
| SCHEMBL6133799 | 0.78 | ADORA2A (0.54) | CDK5CDK5R1KDM4EALDH1A1POLB | |
| SCHEMBL6133893 | 0.78 | FGFR1 (0.43) | CYP1A2AKR1B1FGFR1ADORA2AADORA1 | |
| SCHEMBL6133404 | 0.78 | CYP1A2 (0.37) | CYP1A2CLK1CDK5CDK5R1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2003057689-A1 | AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | CYP1A2 1170/4885CLK1 3624/4885CDK5 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.